EGFR Mutation-Positive Lung Cancer: Clinical Trials

1 active not recruiting. 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	1	Active not recruiting 1

Follow EGFR Mutation-Positive Lung Cancer: new trials by email Literature Review of EGFR Mutation-Positive Lung Cancer trials Research Report on EGFR Mutation-Positive Lung Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study The treatment regimen is Befotertinib combined with Bevacizumab. - Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer	Phase 2	Active not recruiting	Li-kun Chen	70	2024-09-04	2026-10-21

Narrower conditions

Brain Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Meningeal Carcinomatosis (1)

Broader conditions

Brain Diseases (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Central Nervous System Diseases (1)  ·  Central Nervous System Neoplasms (1)  ·  Lung Diseases (1)  ·  Lung Neoplasms (1)  ·  Meningeal Neoplasms (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Nervous System Diseases (1)  ·  Nervous System Neoplasms (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Neoplasms (1)  ·  Thoracic Neoplasms (1)

Interventions

Bevacizumab (1)

Sponsors

Li-kun Chen (1)

Countries

China (1)